Commercial agreement with PETNET Solutions Inc

16 December 2024 - London, UK. IXICO plc (AIM: IXI, "IXICO" or "the Company") a global leader in neuroscience imaging, using its AI-driven platform to help advance therapy research in neurological disorders, today announced a commercial agreement with PETNET Solutions Inc, a Siemens Healthineers company ("PETNET") to supply diagnostic imaging agents to IXICO. This new offering is an integral part of IXICO's expansion strategy to serve its growing customer base with the latest technologies in neuroimaging.

The commercial agreement will see PETNET supplying targeted imaging agents to imaging sites used on IXICO's customers' clinical trials. Further, the agreement adds additional capability to IXICO's growing Tracer Management service offering which provides customers with use guidance, logistics and seamless integration of PET tracers in neurological clinical trials.

PETNET provides radioactive tracers for Positron Emission Tomography ("PET scans"), a widely used diagnostic approach that creates detailed three-dimensional imaging, in this use case, of the inside of the brain. Specific imaging agents may estimate β-amyloid neuritic plaque density in adult patients who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. Another tracer estimates the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease.

Bram Goorden, Chief Executive Officer of IXICO, commented: ''IXICO continues to develop its end to end imaging service for clinical trials, and we are therefore delighted to be partnering with PETNET Solutions to provide access and supply PET tracers. This partnership is an integral part of an expanding offering and our commitment to positively impacting drug discovery and development in critical neurodegenerative illnesses such as Alzheimer's Disease.''

The announcement follows a number of commercial agreements announced throughout 2024 including significant clinical trial contract wins in Huntingdon Disease, Parkinsonian Disorder and Alzheimer's Disease, an MRI algorithm collaboration with Imeka, and a PET tracer supply agreement with Life Molecular Imaging.